Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Research Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SS) on Bullrun: market cap CNY 29.82B, P/E 8.6. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker688192.SS
- ExchangeSS
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCNY
- Market capCNY 29.82B
- P/E8.6
- Financial periodQ2 2026
- RevenueCNY 270.17M
- Net income-CNY 114.82M
- Free cash flow-CNY 86.21M
- Gross margin96.1%
Valuation Snapshot
latest market cap is CNY 29.82B; P/E is 8.6.
Peer valuation comparison
Latest P/E is 8.62x versus a Healthcare sector median of 21.8x (60.5% below).
Latest P/E is 8.62x versus a China median of 16.46x (47.7% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | CNY 29.82B | 8.6 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CNY.
About Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders. Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors.
ETFs that hold Dizal (Jiangsu) Pharmaceutical Co., Ltd.
US-listed ETFs
Dizal (Jiangsu) Pharmaceutical Co., Ltd. is held by 8 US-listed ETFs, going by the latest portfolios they filed with the SEC, most traded first:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Vanguard FTSE All-World ex-US Small-Cap Index Fund ETF Shares (VSS) | 0.01% | 0.06% |
| Vanguard ESG International Stock ETF (VSGX) | <0.01% | 0.10% |
| Northern Trust Morningstar Emerging Markets Factor Tilt ETF (TLTE) | <0.01% | 0.57% |
| Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF (ASHS) | 0.07% | 0.65% |
| Goldman Sachs MarketBeta Emerging Markets Equity ETF (GSEE) | <0.01% | 0.36% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Dizal (Jiangsu) Pharmaceutical Co., Ltd.'s market cap?
Dizal (Jiangsu) Pharmaceutical Co., Ltd.'s market capitalization is CNY 29.82B.
What is Dizal (Jiangsu) Pharmaceutical Co., Ltd.'s P/E ratio?
Dizal (Jiangsu) Pharmaceutical Co., Ltd.'s price-to-earnings (P/E) ratio is 8.6.
What does Dizal (Jiangsu) Pharmaceutical Co., Ltd. do?
Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders. Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. Dizal (Jiangsu) Pharmaceutical Co., Ltd.